九典制藥(300705.SZ):洛索洛芬鈉片獲藥品註冊證書
格隆匯11月9日丨九典制藥(300705.SZ)宣佈,公司於近日收到國家藥監局下發的關於洛索洛芬鈉片60mg規格的藥品註冊證書。洛索洛芬鈉片用於類風濕性關節炎、骨關節炎、腰痛症、肩周炎、頸肩腕綜合徵、牙痛的消炎和鎮痛;手術、外傷及拔牙後的鎮痛和消炎及急性上呼吸道炎的解熱和鎮痛。
截至目前,國內共有10家(含公司)企業取得了洛索洛芬鈉片的藥品註冊批件,其中有2家通過一致性評價,公司該品種是按照新註冊分類4申報,視同通過一致性評價。該藥品註冊證書的取得進一步豐富了公司製劑產品品種,對進一步優化公司產品結構有着積極意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.